Actively Recruiting
Phase 1 Study to Assess Safety and Effects of ALN-6222 in Adults with Obesity
Led by Alnylam Pharmaceuticals · Updated on 2026-08-12
88
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are conducting a Phase 1, randomized, double-blind, placebo-controlled study to assess ALN-6222s safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy in adults with obesity. This first-in-human trial focuses on participants with a body mass index between 30 and less than 40 kgm and aims to monitor adverse events and biological markers over time. Participants will receive a single subcutaneous dose of either ALN-6222 or a placebo. The study uses a parallel design with random allocation and triple masking to compare these two groups. The treatment period includes a single dose administration followed by monitoring and assessments extending up to 12 months postdose. During the study, participants will undergo evaluations including blood tests to measure drug concentrations and changes in protein markers. Safety is closely monitored by tracking adverse events for up to 12 months. The total participation duration includes dosing and long-term follow-up to evaluate the drugs effects and tolerability in adults with obesity.
CONDITIONS
Brief Title
A Study to Evaluate ALN-6222 in Participants With Obesity
Research Team
A
Alnylam Clinical Trial Information Line
A
Alnylam Clinical Trial Information Line
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
